Clinical Trial

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 28, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination with another anti-cancer drug * Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-07-29
notable Trial sites reduced: 35 -> 26 locations 2026-07-29
Trial Details
NCT Number NCT06507306
Lead Sponsor Kumquat Biosciences Inc.
Conditions Solid Tumor, Adult
Enrollment 92 participants
Start Date 2024-06-03
Primary Completion 2026-07-31 (estimated)
Study Completion 2027-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-28